Diabetes Trial Files: Semaglutide for Cardiac Function in Obesity-Related HFpEF, Dapagliflozin + Calorie Restriction for T2DM Remission, and Dapagliflozin and Linagliptin in T2DM
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure
Solomon SD et al. JACC (October 2024)
Bottom Line: This study, part of the STEP-HFpEF Program, evaluated the effects of once-weekly semaglutide (2.4 mg) on cardiac structure and function in patients with obesity-related HFpEF. A total of 491 participants were included in the study, with 253 receiving semaglutide and 238 receiving placebo. The primary outcome was change in left atrial (LA) volume at 52 weeks, and semaglutide showed significant improvement in LA remodeling and right ventricular enlargement compared to placebo. Other secondary outcomes, such as E-wave velocity and E/A ratio, also showed improvement with semaglutide. These results suggest that semaglutide may be a disease-modifying treatment for patients with obesity-related HFpEF.
Dapagliflozin plus calorie restriction for remission of type 2 diabetes
Liu Y et al. BMJ (January 2025)
Bottom Line: This is a multicentre, double blind, randomised, placebo controlled trial conducted in mainland China from June 2020 to January 2023. The study included 328 patients with type 2 diabetes aged 20-70 years, with body mass index >25 and diabetes duration of <6 years. The intervention group received calorie restriction with dapagliflozin 10 mg/day while the comparator group received placebo. The primary outcome was the incidence of diabetes remission at 12 months, which was achieved in 44% of patients in the intervention group and 28% of patients in the control group. The intervention group also showed significant improvements in body weight and insulin resistance compared to the control group. No significant differences were seen in adverse events between the two groups. The study concluded that the combination of dapagliflozin and calorie restriction was more effective in achieving remission of type 2 diabetes compared to calorie restriction alone.
Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus
Hong JH et al. Diabetes, Obesity and Metabolism (October 2024)
Bottom Line: This randomized controlled trial evaluated the efficacy and safety of add-on dapagliflozin in patients with type 2 diabetes mellitus (T2D) who had inadequate glycaemic control with metformin and linagliptin. A total of 235 patients were randomized to receive either dapagliflozin/linagliptin fixed-dose combination (FDC [AJU-A51]) 10/5 mg/day or linagliptin 5 mg plus placebo for 24 weeks. The primary outcome was change in glycated haemoglobin (HbA1c) from baseline to Week 24. The intervention group had a significantly greater reduction in HbA1c compared to the comparator group (p<0.0001). Both groups had similar incidence of treatment-emergent and serious adverse events, and no cases of symptomatic hypoglycaemia were reported. Dapagliflozin and linagliptin FDC (AJU-A51) showed potent glucose-lowering effects, with good tolerability, in patients with T2D who had poor glycaemic control on metformin and linagliptin.
Diabetes Trial Files Issue #DIA-2025-03
Want to view past issues? Visit our archive:
